This is going to be fun!
Blog
On Friday, January 29th 2021 an article about Murrieta Genomics and our wholly owned subsidiary, SimplSEQ, was published by GenomeWeb.
We anticipate a high level of demand for our products, as they will allow labs to save money, time and
Murrieta Genomics was recently named as a “company to watch” by The Healthcare Insights, a medical publication that discusses developments
Press Releases
“The simplSEQ workflow offers many workflow advantages over other methods of cell-free DNA extraction especially speed, simplicity, reproducibility, which are
Company Filed Second Patent Application to Extend Core Technology Applications
Murrieta Genomics is pleased to announce that U.S. Patent and Trademark
Murrieta Genomics, the launch pad for genomic sequencing startups, is pleased to announce that simplSEQ, an incubator company and subsidiary,
“Our first product is a kit for the purification and isolation of nucleic acids from plasma that we believe will
Blog
This is going to be fun!
On Friday, January 29th 2021 an article about Murrieta Genomics and our wholly owned subsidiary, SimplSEQ, was published by GenomeWeb.
We anticipate a high level of demand for our products, as they will allow labs to save money, time and
Murrieta Genomics was recently named as a “company to watch” by The Healthcare Insights, a medical publication that discusses developments
Press Releases
“The simplSEQ workflow offers many workflow advantages over other methods of cell-free DNA extraction especially speed, simplicity, reproducibility, which are
Company Filed Second Patent Application to Extend Core Technology Applications
Murrieta Genomics is pleased to announce that U.S. Patent and Trademark
Murrieta Genomics, the launch pad for genomic sequencing startups, is pleased to announce that simplSEQ, an incubator company and subsidiary,
“Our first product is a kit for the purification and isolation of nucleic acids from plasma that we believe will